Covid-19 roundup: Atea Phar­ma­ceu­ti­cals launch­es an­tivi­ral in­to PhI­II tri­al; Cell­tri­on's an­ti­body shows promise ...

5 years ago
Coronavirus

A new gene ther­a­py play­er de­buts in LA with 2 start­up VCs at its back, Ab­b­Vie on board with a $90M cash up­front and ...

5 years ago
Startups

The biotech craze hits the Nordics, dri­ving a record-high $62M Se­ries A for a Copen­hagen-based ADC play­er

5 years ago
Financing

Mod­er­na tur­bocharges its sup­ply chain, up­ping com­mit­ment to 3B dos­es per year for a fu­ture where boost­ers are like­ly

5 years ago
Outsourcing
Coronavirus

Gene ther­a­py tri­al is de­railed af­ter get­ting hit by the lat­est se­ri­ous ad­verse event in the field — shares crash

5 years ago
Cell/Gene Tx

Gene ther­a­py deaths push back Astel­las-Au­den­tes' ap­proval by at least two years

5 years ago
Cell/Gene Tx

ODAC votes to keep Keytru­da and Tecen­triq ac­cel­er­at­ed ap­provals in blad­der can­cer

5 years ago
Pharma
FDA+

FDA warns Ac­celeron of pos­si­ble fines for not post­ing re­sults from failed tri­al

5 years ago
FDA+

With Amy Aber­nethy out, Vid De­sai takes over as FDA’s act­ing CIO

5 years ago
FDA+

The pres­sure builds for Em­ma Walm­s­ley as Glax­o­SmithK­line miss­es Q1 pro­jec­tion, drops more can­cer drugs

5 years ago
Pharma

PureTech turns 200-year-old dis­cov­ery in­to a new ap­proach to Alzheimer's, while cling­ing to con­tro­ver­sial amy­loid ...

5 years ago
Discovery

BeiGene's late stage tri­al shows promis­ing num­bers; Am­gen to study so­tora­sib dosage af­ter FDA rec­om­men­da­tion

5 years ago
News Briefing

Tril­li­um is hunt­ing gi­ants with its an­ti-CD47 drug, but ques­tions over a high-dose so­lo reg­i­men still linger

5 years ago
R&D

What caused Roche's Hunt­ing­ton's drug tomin­ersen to hit the skids in late-stage test? It's com­pli­cat­ed, an­a­lysts say

5 years ago
R&D

US ups fund­ing for Mod­er­na Covid-19 vac­cine as to­tal nears $6B

5 years ago
Financing
Coronavirus

Opin­ion: Mean­ing­ful drug pric­ing re­forms are head­ed nowhere fast

5 years ago
Pharma
FDA+

Bound­less Bio rais­es $105M in ef­fort to reimag­ine tar­get­ed can­cer ther­a­py

5 years ago
Financing

Covid-19 roundup: Eu­ro­pean Com­mis­sion's le­gal bat­tle against As­traZeneca be­gins; Kaza­khstan gives green light to ...

5 years ago
Coronavirus

Am­plyx laid out a promis­ing path to a piv­otal an­ti­fun­gal drug tri­al, and now Pfiz­er is scoop­ing it all up in a buy­out

5 years ago
Deals

Sanofi re­ports sales growth amid Dupix­en­t's Chi­na launch, but re­veals PDU­FA de­lay in Pompe dis­ease pro­gram

5 years ago
Pharma

Fu­eled with a fresh half-bil­lion dol­lars as AI in­vest­ments boom, Ex­sci­en­tia is hit­ting the gas on drug de­vel­op­ment

5 years ago
Financing
AI

Ex­clu­sive: Ohana, Flag­ship's big bet on fer­til­i­ty treat­ments, shuts down and lays off staff af­ter VC pulls the plug

5 years ago
Startups

Tech glitch­es over­shad­ow FDA on­col­o­gy ad­comm as a sol­id ma­jor­i­ty of ad­vis­ers vote to keep Roche's Tecen­triq in mTNBC

5 years ago
R&D
FDA+

Eli Lil­ly shares take a hit as com­pa­ny low­ers full-year fore­cast

5 years ago
Pharma
First page Previous page 700701702703704705706 Next page Last page
A service from the Financial Times